Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Gary L. Eddy"'
Autor:
Gary L. Eddy, Michael T. Mazur, Serdar H. Ural, Pamela S. Piraino, Martha A. Wojtowycz, Kenneth B. Strumpf
Publikováno v:
Gynecologic Oncology. 67:51-55
To establish the frequency of the atypical glandular cells of uncertain significance (AGCUS) category, and its subcategories, as defined by the Bethesda System (TBS).Our computerized records of cervical/vaginal cytology specimens submitted from Janua
Publikováno v:
Gynecologic Oncology. 57:412-416
Thirty-five patients with bulky (designated as > or = 4 cm size) International Federation of Gynaecology and Obstetrics (FIGO) Stage IB cervical cancer were treated with cisplatin, 50 mg/m2, and vincristine, 1 mg/m2, administered intravenously at 10-
Publikováno v:
Gynecologic Oncology. 55:313-317
Electrosurgical loop conization of the cervix is a new procedure that is being rapidly accepted for treatment of cervical intraepithelial neoplasia (CIN). Concerns include fragmentation of the specimen that is frequently mandated by the size of the t
Autor:
Gary L. Eddy, William T. Creasman
Publikováno v:
Seminars in Surgical Oncology. 6:339-342
There are well-defined prognostic factors that identify patients with clinical stage I (confined to the uterus) endometrial adenocarcinoma and patients at high risk vs. low risk for recurrent disease and allow for treatment tailored to those specific
Autor:
Edward V. Hannigan, Brian N. Bundy, Nick M. Spirtos, Dennis M. O’Connor, Gary L. Eddy, Robert S. Mannel, William T. Creasman
Publikováno v:
Gynecologic oncology. 106(2)
Objective A randomized phase III trial was conducted to determine if neoadjuvant chemotherapy (NACT) prior to radical hysterectomy and pelvic/para-aortic lymphadenectomy (RHPPL) could improve progression-free survival (PFS) and overall survival (OS),
Secretory Endometrial Adenocarcinoma in a Patient on Tamoxifen for Breast Cancer: A Report of a Case
Publikováno v:
Gynecologic Oncology. 58:133-135
Well-differentiated endometrial adenocarcinoma of the secretory type (FIGO Grade 1) with minimal myometrial invasion occurred in a postmenopausal patient on tamoxifen therapy 5 years after mastectomy for breast carcinoma. We believe that this is the
Publikováno v:
Obstetrics and gynecology. 90(6)
Objective: To evaluate the prognostic significance of the Bethesda system’s cytologic categories in patients with endometrial malignancy. Methods: Patients with biopsy or hysterectomy-proven endometrial malignancy and a Papanicolaou smear result re
Publikováno v:
American journal of obstetrics and gynecology. 177(5)
Histologic findings in biopsy specimens obtained from patients with atypical glandular cells of uncertain significance were studied to define the utility and limitations of this category.Computerized records over a 3-year period were retrospectively
Autor:
Gary L. Eddy
Publikováno v:
Gynecologic oncology. 65(2)
The presence of a pelvic mass in a patient with an elevated serum CA-125 suggests the possibility of a gynecologic malignancy. However, an increasing number of nonneoplastic causes of elevated serum CA-125 have been reported. This is the first report
Publikováno v:
American journal of clinical oncology. 16(1)
Thirty-three evaluable patients who had not received prior chemotherapy were entered on a study of vincristine therapy for advanced or recurrent endometrial carcinoma. Vincristine 1.4 mg/m2 was given weekly as an i.v. bolus for 4 weeks and then every